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A cute interstitial nephritis (AIN) is an importantand common cause of acute kidney injury. The
established causes of AIN include drugs, infections,
and autoimmune diseases. In a small number of cases,
no obvious cause can be identiﬁed.1,2 The classical
presentation of AIN with hypersensitivity symptoms
such as skin rash, eosinophilia, and fever, largely
induced by antibiotics, has been replaced mainly by
less classical manifestations in elderly patients with
nonsteroidal antiinﬂammatory agents and proton
pump inhibitors as the offending agents.3 Drug-
induced AIN remains the most common etiology of
AIN; however, it is important to include other entities
such as tubulointerstitial nephritis with uveitis syn-
drome, IgG4-related disease, systemic lupus erythe-
matosus, sarcoidosis, and other systemic diseases in
the differential diagnosis. AIN is characterized histo-
logically by heavy interstitial inﬁltrate of inﬂamma-
tory cells mainly T-lymphocytes and macrophages,
with variable numbers of plasma cells, eosinophils,
neutrophils, and noncaseating granulomas.4 The in-
ﬁltrates can be patchy or diffuse and are concentrated
in the deep cortex and the outer medulla. In addition
to inﬁltrative lesions and interstitial edema, tubular
lesions range from mild cellular changes to widespread
epithelial cell necrosis.5 Traditionally, the treatment
consists of the removal of the offending drugs, if
known, along with steroid therapy. Steroids are
administered as high doses and followed by a rapid
taper.6–8 Corticosteroid-dependent, relapsing AIN
continues to be an important therapeutic challenge in
the treatment of AIN.3 The present report indicates
that therapy speciﬁcally targeted at the T cells usingInternational Reports (2016) -, -–-antithymocyte globulin (ATG) can dramatically alter
the course of the disease, in some cases.CASE PRESENTATION
The patient is a 43-year-old woman with a medical
history of bipolar disorder, untreated hepatitis C,
substance abuse, and psoriasis, who presented in July
2014 with a 4-day history of nausea, vomiting, diar-
rhea, and acute kidney injury with a serum creatinine
of 1170 mmol/l. Renal ultrasound demonstrated normal-
sized kidneys without hydronephrosis. Both infectious
and malignancy workup were negative, and there were
no offending drugs identiﬁed in the history or toxi-
cology screen. Her serology revealed low C3 of
0.63 (reference 0.79–1.52), normal C4, and a positive
cytoplasmic antineutrophil cytoplasmic antibody with
anti-PR3 of 10.8 (reference < 3.5). Antinuclear anti-
body was 1.1 (reference # 1.0) and anti-DNA antibody
was normal. Furthermore, the patient did not fulﬁll the
clinical criteria for systemic lupus erythematosus.
She was admitted with a diagnosis of acute kidney
injury. Her renal biopsy showed AIN with a predomi-
nately lymphocytic inﬁltrate (Figure 1a and c). The
immunoﬂuorescence microscopy showed 12 glomeruli
with mesangial staining for IgA (1þ), IgM (trace), C3
(1þ), kappa (trace) and lambda (trace to 1þ), and no
staining for IgG. Electron microscopy showed a het-
erogeneous cellular inﬁltrate in the interstitium
composed of activated lymphocytes and occasional
plasma cells. It was accompanied by acute degenerative
changes in the tubular cells, including marked alter-
ations of the brush border. Occasional electron-
dense deposits were found with a coarse granular
structure, not typical of immune deposits. Overall, the1
Figure 1. (a) Renal biopsy before treatment on 18 July 2014 (hematoxylin and eosin stain). (b) Renal biopsy after treatment on 18 April 2016
(hematoxylin and eosin stain). (c) T-lymphocyte interstitial inﬁltrate before treatment. The mean number of T cells per mm2 is 3835  436 (CD3
immunohistochemical marker). (d) T-lymphocyte infiltrate after treatment (CD3 immunohistochemical marker). The mean number of T cells per
mm2 is 663  184 (P < 0.0005) (CD3 immunohistochemical marker).
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diagnosis of interstitial nephritis and no evidence of
glomerular changes associated with ANCA vasculitis or
systemic lupus erythematosus. The etiology of the AIN
remained unclear, and hemodialysis and pulse steroid
therapy (500 mg IV for 3 days, followed by 65 mg PO
daily) were instituted. There was no evidence of uveitis.
As there was no improvement, mycophenolate 500 mg 3
times daily was added. She remained hemodialysis
dependent and was otherwise well. As there was no
etiological basis identiﬁed, and as she tolerated the
therapy well, treatment was continued longer than
usual. A renal ultrasound was obtained to establish
whether chronic changes had occurred, and as the renal
size was unchanged and as there was no increased
echogenicity, a repeat renal biopsy was carried out 4
months after the initial presentation. The second biopsy
appeared very similar to the ﬁrst, with a prominent
cellular inﬁltrate and little scarring (the P value for the2number of T-lymphocytes between biopsy 1 and 2 was
0.125). The levels of the third and fourth components of
complement had normalized, the ANCA assay was
negative on 2 occasions, the extractable nuclear antigen
antibodies screen was negative, the anti-DNA AB was
normal, and serum IgG was within the normal range. As
T cells remained the predominant cells in the inﬁltrate,
she was admitted for speciﬁc anti-T-cell therapy. She
received a total of 600 mg (10 mg/kg) of rabbit ATG
(Thymoglobulin, Sanoﬁ-Aventis, Laval, PQ, Canada) in
8 infusions from 29 November to 9 December 2014.
Hemodialysis was no longer necessary 2 months after
the initiation of ATG therapy, and her serum creatinine
continued to fall (from the 400 range, while on chronic
hemodialysis) and reached its nadir 10 months after the
ﬁnal antithymocyte globulin infusion. The serum
creatinine remained stable in the 140 mmol/l range. At
this time she was receiving 15 mg of prednisone daily
and 720 mg of mycophenolate twice daily. To establishKidney International Reports (2016) -, -–-
Table 1. Number of T cells in each of the 3 biopsies
Date of renal biopsy Number of T cells per mm2 ± SD
18 July 2014 3835  436
6 November 2014 3280  51
18 April 2016 663  184*
*P < 0.005 biopsy 1 versus biopsy 3.
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mation accounting for the remaining renal function
impairment (requiring additional therapeutic interven-
tion), a third biopsy was carried out 16 months after
completion of the ATG infusions. This indicated
a patchy inﬁltrate of lymphocytes in the interstitium,
with a marked decrease in the density of T-lymphocytes
that were evaluated by quantitative immunohisto-
chemistry (Figure 1b and d) (Table 1). Additional
immunohistochemical characterization (not illustrated)
of the cell populations in the inﬂammatory cell inﬁltrate
in the pretreatment biopsy showed that the large ma-
jority of the T cells were T helper cells, whereas T
suppressor cells were present in a smaller proportion,
with an approximate ratio of 9 to 1, respectively. Plasma
cells, identiﬁed with the CD138 marker, were rare. In
addition, cells of the monocytes/macrophages lineage,
identiﬁed with the CD163 marker, were present at
high frequency in the interstitial inﬁltrate. There was
no signiﬁcant number of natural killer cells. After the
ATG treatment, there was a marked and parallel
decrease in T helper cells, T suppressor cells, and
monocytes/macrophages.
DISCUSSION
The main aim in the treatment of AIN is to arrest the
inﬂammatory reaction, by removing the inciting agent,
and depleting the inﬂammatory cells from the renal
parenchyma. In this respect, corticosteroids are
frequently used, but the effectiveness of their role
remains controversial.7,9,10 AIN is postulated to be an
immune-mediated disorder driven by T cells primarily.
Therefore, an immunosuppressive regimen using cor-
ticosteroids is the commonly used treatment for AIN.
Corticosteroids exert their antiinﬂammatory effects by
interrupting multiple steps in signal transduction
pathways given the ubiquitous expression of gluco-
corticoid receptors. Corticosteroids function by acti-
vating glucocorticoid receptors to directly or indirectly
regulate the transcription of target genes to inhibit
antigen presentation, cytokine production, and prolif-
eration of lymphocytes.11 In this case, after a period of
lack of response to steroids, mycophenolate was added
to her therapy. Mycophenolate exerts its immunosup-
pressive effects through the inhibition of the rate-
limiting enzyme in the de novo pathway of purineKidney International Reports (2016) -, -–-synthesis and in turn decreases T- and B-lymphocyte
proliferation and reduces antibody production.12 ATG
is a puriﬁed polyclonal Ig, directed against human
thymocytes. The mechanism of action on the immune
response is not fully understood; however, its primary
mechanism is through T-cell depletion by inducing
lymphocyte depletion in the peripheral blood by
complement-dependent cell lysis.13
In the present case, there was little impact of therapy
with steroids and mycophenolate. However, we
observed an 80% decrease in the density of
T-lymphocytes in the interstitium after ATG therapy
coupled with a dramatic and sustained improvement in
the renal function, allowing cessation of hemodialysis.
No clinically signiﬁcant side effects of the ATG
therapy were observed during the treatment of the
patient. Hematological studies showed however that
there was a 56% decrease (1.221–0.54  109/L) in
the number of circulating lymphocytes, as might be
expected from the cellular target of the drug.
To conclude, the present report is the ﬁrst to show a
dramatic response to ATG therapy in a patient with
acute interstitial nephritis who was previously steroid
resistant and hemodialysis dependent. The most recent
serum creatinine (4 August 2016) was 125 mmol/l. This
case raises the concern that perhaps patients with
potentially reversible disease remain on hemodialysis,
due to failure to respond to initial conventional therapy.
Such patients, if an ultrasound suggests the absence of
chronic changes, should undergo a repeat renal biopsy
to identify the possible target for more speciﬁc therapy.
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